AtriCure (Nasdaq:ATRC) this week posted first-quarter results that beat the overall consensus on Wall Street.

The Mason, Ohio-based cardiac ablation device company reported losses of $15.2 million, or -34¢ per share, on sales of $74.6 million for three months ended March 31, for a bottom-line gain of 10.3% on sales growth of 25.8% compared with Q1 2021.

Earnings per share were 1¢ ahead of The Street, where analysts were looking for sales of $71.17 million.

“Our team delivered exceptional first-quarter performance, with broad-based growth across all key products,” CEO Michael Carrel said in a news release. “With EPi-Sense adoption building, continued expansion of our Cryo Nerve Block team, and the full commercial launch of our EnCompass clamp now underway, we are confident in the strength of our portfolio today while we invest in additional long-term drivers for sustained growth.”

AtriCure expects full-year 2022 revenue to be in the range of $318 million to $330 million to reflect a growth of approximately 16% to 20% over full-year 2021.

Shares in ATRC were down 1.65% to $53.73 apiece at market open.